Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Adrestia Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with Adrestia’s expertise in target biology with a novel synthetic rescue drug development platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Adrestia Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : $73.3 million
Deal Type : Collaboration
Proteros to Receive Research Funding AND Milestone Payments Plus Royalties
Details : Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : $73.3 million
Deal Type : Collaboration